BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/26/2024 9:19:14 AM | Browse: 124 | Download: 280
 |
Received |
|
2024-08-03 19:55 |
|
Peer-Review Started |
|
2024-08-03 19:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-08-17 03:11 |
|
Revised |
|
2024-08-29 02:50 |
|
Second Decision |
|
2024-09-10 02:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-09-10 06:19 |
|
Articles in Press |
|
2024-09-10 06:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-18 08:47 |
|
Publish the Manuscript Online |
|
2024-09-26 08:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Qin Wang, Di Pan, Zhi-Yuan Yao, Yu-Qi Li, Peng-Fei Qu, Run-Bang Wang, Qing-Hao Gu, Jie Jiang, Zheng-Xiang Han and Hao-Nan Liu |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hao-Nan Liu, Doctor, Doctor, Doctor, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Quanshan District, Xuzhou 221000, Jiangsu Province, China. why974300@163.com |
| Key Words |
Hepatocellular carcinoma; Camrelizumab; Lenvatinib; Efficacy; Safety |
| Core Tip |
Primary liver cancer is the sixth most common cancer and the third leading cause of cancer-related death worldwide, with hepatocellular carcinoma (HCC) being the most prevalent form. Numerous combination therapies involving programmed cell death protein 1/programmed cell death ligand 1 inhibitors and antiangiogenic targeted therapies have been investigated and approved as first-line systemic therapy for patients with advanced HCC. In the era of immune checkpoint inhibitors, nutritional assessment, including body mass index (BMI), can be considered a new prognostic predictor. However, the impact of BMI on the prognosis of patients with hepatitis B virus-related HCC remains controversial. We initiated a retrospective clinical study to explore the impact of BMI level on the prognosis of hepatitis B virus-related HCC patients treated with lenvatinib plus carelizumab. |
| Publish Date |
2024-09-26 08:22 |
| Citation |
<p>Wang YQ, Pan D, Yao ZY, Li YQ, Qu PF, Wang RB, Gu QH, Jiang J, Han ZX, Liu HN. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. <i>World J Gastroenterol</i> 2024; 30(37): 4132-4148</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i37/4132.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i37.4132 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
